Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Neven

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Current Opinion in Obstetrics & Gynecology|March 4, 1998
Controversies regarding tamoxifen and uterine carcinomaP Neven, I Vergote
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 31, 2001
Tamoxifen, screening and new oestrogen receptor modulatorsP Neven, I Vergote
Drug Safety|January 27, 2000
Guidelines for monitoring patients taking tamoxifen treatmentP Neven, H Vernaeve
Histopathology|April 1, 1991
Invasive adenocarcinoma arising in extramammary Paget's disease of the vulvaA T Evans, P Neven
Acta Clinica Belgica|September 24, 2011
Breast cancer prevention: lifestyle changes and chemopreventionS Lambrechts, J Decloedt, P Neven
European Journal of Obstetrics, Gynecology, and Reproductive Biology|September 23, 1992
An unusual type of endometrial cancer, related to tamoxifen?J Deprest, P Neven, P Ide
ESMO Open|July 5, 2021
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscapeE Adams, H Wildiers, P Neven, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Modulation of endometrial transforming growth factor beta (TGFbeta) by tamoxifenP L Carmichael, J C Pole, P Neven
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patientsL Morales, D Timmerman, P Neven, et al.
Maturitas|December 28, 2010
Management of menopausal symptoms in breast cancer patientsS Loibl, A Lintermans, A S Dieudonné, et al.
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Current Opinion in Obstetrics & Gynecology|March 4, 1998
Controversies regarding tamoxifen and uterine carcinomaP Neven, I Vergote
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 31, 2001
Tamoxifen, screening and new oestrogen receptor modulatorsP Neven, I Vergote
Drug Safety|January 27, 2000
Guidelines for monitoring patients taking tamoxifen treatmentP Neven, H Vernaeve
Histopathology|April 1, 1991
Invasive adenocarcinoma arising in extramammary Paget's disease of the vulvaA T Evans, P Neven
Acta Clinica Belgica|September 24, 2011
Breast cancer prevention: lifestyle changes and chemopreventionS Lambrechts, J Decloedt, P Neven
European Journal of Obstetrics, Gynecology, and Reproductive Biology|September 23, 1992
An unusual type of endometrial cancer, related to tamoxifen?J Deprest, P Neven, P Ide
ESMO Open|July 5, 2021
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscapeE Adams, H Wildiers, P Neven, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Modulation of endometrial transforming growth factor beta (TGFbeta) by tamoxifenP L Carmichael, J C Pole, P Neven
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patientsL Morales, D Timmerman, P Neven, et al.
Maturitas|December 28, 2010
Management of menopausal symptoms in breast cancer patientsS Loibl, A Lintermans, A S Dieudonné, et al.
Pageof 14